Regulatory actions for June 10, 2026
AI Briefing
- • Atavistik's biologics license application approved by the US FDA for rare genetic disorder treatment.
- • Zai Lab's cancer treatment approved by the US FDA for advanced kidney cancer patients.
- • Redhill's experimental treatment for rare neurological disorder gains FDA Fast Track designation.
Context
Regulatory actions are being reported for June 10, 2026. Companies involved include Atavistik, Chiesi, Disc, Gen1e, Matisse, Personalis, Redhill, Vertanical, Xenix, and Zai Lab.
These actions include global submissions and approvals, as well as other regulatory decisions and designations for biopharma and med tech companies.
Advertisement